Organization
Teva Pharmaceuticals
7 clinical trials
1 abstract
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY® (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal AtrophyStatus: Completed, Estimated PCD: 2024-03-15
Clinical trial
Study to Evaluate the Efficacy, Safety, Tolerability, and Immunogenicity of TEV-45779 Compared to XOLAIR (Omalizumab) in Patients With Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic Despite Antihistamine (H1) Treatment.Status: Completed, Estimated PCD: 2023-09-19
Clinical trial
A Randomized, Double-Blind, Multinational, Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of TVB-009P and Denosumab (Prolia®) in Patients With Postmenopausal OsteoporosisStatus: Completed, Estimated PCD: 2022-12-31
Clinical trial
A Relative Bioavailability Study of 40 mg Benazepril Hydrochloride Tablets Under Non-Fasting ConditionsStatus: Completed, Estimated PCD: 2001-03-01
Clinical trial
A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, THREE-ARM, PLACEBO CONTROLLED, PARALLEL-DESIGN GROUP STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE COMPARING TRIFAROTENE CREAM, 0.005% (TEVA PHARMACEUTICALS, INC. TO AKLIEF ® (TRIFAROTENE 0.005% CREAM) (GALDERMA LABORATORIES, L.P., USA), IN THE TREATMENT OF ACNE VULGARISStatus: Completed, Estimated PCD: 2023-01-23
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Nasal Spray, 50 mcg With Flonase® Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic RhinitisStatus: Terminated, Estimated PCD: 2014-07-14
Clinical trial
The Relative Bioavailability of Two Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting ConditionsStatus: Completed, Estimated PCD: 2002-01-01
Abstract
Extracorporeal removal of soluble tumor necrosis factor receptors for the treatment of advanced refractory solid tumors.Org: Immunicom, Inc., Sheba Medical Center, Or-Yeuda, Rabin Medical Center Davidoff Cancer Centre, Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Teva Pharmaceuticals,